Overview

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)